Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial
George Maynard, Stephen M. Strittmatter(Yale University), Charles Y. Liu(University of Southern California), Adam E. Flanders(Jefferson University Hospitals), Crista L. Adamson, Ralph J. Marino(Icahn School of Medicine at Mount Sinai), R. Kannan(Yale University), David C. Chen(University of California, Los Angeles), Jan M. Schwab(The Ohio State University Wexner Medical Center), Craig Hackett(Sepragen Corporation (United States)), Erika Smith, Weiwei Wang(W. M. Keck Foundation), Xingxing Wang(Jiangxi Agricultural University), Tu Kiet T. Lam(W. M. Keck Foundation), Jian Liu(Yale University), Ross Zafonte(Harvard University), Gilbert Block, Donald Leslie(Shepherd Center)
Cited by 55
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Central nervous system injury-induced immune deficiency syndrome
|Nature reviews. Neuroscience|2005|948
A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury
|Brain Imaging and Behavior|2012|935
N‐methyl‐<scp>D</scp>‐aspartate receptor antibodies in herpes simplex encephalitis
|Annals of Neurology|2012|414